Early Risk Assessment in TB contacts by new diagnostic tests (ERASE-TB)

Principal Investigators: Katherina Kranzer and Norbert Heinrich
Site Principal Investigator: Dr. Theodora Mbunda
Other Investigators: Dr. Nyanda Elias Ntinginya, Dr. Issa Sabi, Dr. Christina Manyama, Dr. Alfred Mfinanga, Dr. Harieth Mwambola
Research Centre: NIMR -MMRC, Mbeya Tanzania.
Study Duration: 2020-2024

Background / Purpose

The ERASE-TB study is being conducted to fill a critical unmet need for tuberculosis (TB) control. People who encounter an infectious TB case may become infected, and, among those who are do, most will stay healthy. However, some will go on to develop TB and such people would benefit from preventive treatment which would also inhibit the spread of the disease. 

Delayed diagnoses hampers tuberculosis (TB) control: globally, over four million TB cases remain undiagnosed each year. Bacterial burden and infectiousness are high, and lung damage is extensive in patients experiencing diagnostic delays.

The aim of this prospective multi-centre cohort study among household contacts (HHC), exposed to smear positive, infectious tuberculosis (TB) index cases is to evaluate new diagnostic tests and algorithms to diagnose TB before transmission occurs, earlier than current diagnostic approaches and to identify those most at risk for developing TB to allow targeted preventive treatment.

Clearly, earlier diagnosis is a prerequisite for successful TB control and ideally, individuals need to be diagnosed while TB is still incipient before becoming infectious. Preventive treatment of incipient TB could prevent long term morbidity, mortality, and onward transmission.


ERASE-TB will conduct a clinical cohort study among 2100 adolescent and adult household contacts (HHCs) exposed to smear positive, infectious TB in three HIV and TB high-burden Sub-Saharan African countries (Mozambique, Tanzania and Zimbabwe) to generate performance data on a number of new diagnostic assays, sampling strategies and testing algorithms to diagnose sub-clinical TB and accurately predict progression to disease with the aim of WHO endorsement and rapid in-country uptake and roll-out.


ERASE-TB is an EDCTP project funded by the European Commission under Grant Agreement no. RIA2018D32508.

ERASE-TB Partners:

  • Medical Centre of the University of Munich (LMU)
  • London School of Hygiene & Tropical Medicine (LSHTM)
  • Biomedical Research and Training Institute (BRTI) Zimbabwe 
  • National Institute for Medical Research (NIMR) Tanzania
  • Instituto Nacional de Saude (INS) Mozambique 
  • Dept. of Clinical Science & Education, Karolinska Institute 

Website: https://www.erase-tb.co.uk
Twitter: @EraseTb



You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya Implementation of the Decetralized Sequencing under SeqTz project in Mbeya region on pathogens genomics in relatio… https://t.co/WGb92oX6s2
NIMRMbeya RT @wizara_afyatz: “Tafiti zinaonesha kuwa kila siku wanawake zaidi ya milioni 300 wenye umri kati ya miaka 15 hadi 49 wanakuwa kwenye hedh…
NIMRMbeya RT @UKinTanzania: The 🇬🇧 is proud to support @wizara_afyatz's goal of strengthening health care systems to achieve Universal Health Coverag…
© 2017 NIMR - Mbeya Medical Research Center